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ABSTRACT
Clinical neuroimaging is increasingly being used in the diagnosis of neurodegenerative diseases and has become
one of the most important paraclinical tools in the diagnosis of dementia. According to current guidelines,
neuroimaging, preferably magnetic resonance imaging (MRI), should be performed at least once during the
diagnostic work-up of patients with suspected or definite dementia. MRI is helpful in identifying or excluding
potentially treatable causes of dementia; however, these account only for a small proportion of dementias.
In addition, MRI is able to support the clinical diagnosis in a memory clinic setting by identifying certain
patterns of atrophy and vascular damage. Visual rating scales are well-established methods in the clinical
routine for the assessment and quantification of regional/global cortical atrophy, hippocampal atrophy and
vascular damage. In addition, MRI is able to detect certain aspects of pathology associated with dementia,
such as cerebral microbleeds which are related to cerebral amyloid angiopathy and Alzheimer pathology. This
review paper aims to give an overview of the application of structural MRI in the diagnostic procedure for
memory clinic patients in terms of excluding and supporting the diagnosis of various diseases associated with
dementia.
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Introduction
Clinical neuroimaging is increasingly being used in
the diagnostic work-up of patients presenting to a
memory clinic. Structural neuroimaging methods
such as computed tomography (CT) and, more
sensitively, magnetic resonance imaging (MRI)
are well suited to exclude possibly (surgically)
treatable cause of dementia (e.g. tumors, subdural
hematomas, hydrocephalus, etc.). However, these
patients represent the vast minority (<8%) of
patients presenting with memory complaints
to a memory clinic (Scheltens et al., 2002).
More importantly, structural brain imaging can
demonstrate certain patterns of atrophy, vascular
pathology or inflammatory changes, which can
substantially support the clinical diagnosis of
dementia. In other words, during the past decade,
the role of structural neuroimaging as a diagnostic
tool in a memory clinic setting has changed from
an exclusionary to a more inclusionary approach.
In addition, MRI is increasingly being used for
disease monitoring (e.g. progression of atrophy
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and vascular changes) and has therefore been
established as a valuable method for efficacy and
safetymonitoring in clinical treatment trials (Frisoni
et al., 2010). As a consequence, this has led to the
incorporation of clinical neuroimaging into current
diagnostic guidelines of dementia, which state that
neuroimaging should be performed at least once
during the diagnostic work-up of patients with
suspected or definite dementia (Hort et al., 2010).
Structural MRI protocol in dementia
Multidetector CT is a suitable diagnostic method
for the exclusion of possible treatable causes of
dementia, as well as for the assessment and visual
rating of focal and global cortical atrophy, atrophy
of the medial temporal lobe and vascular white
matter changes (Wattjes et al., 2009). However,
structural MRI is the imaging modality of choice
due to the lack of radiation, better graymatter/ white
matter contrast, and the ability to manipulate tissue
contrast with different pulse sequences.
The MRI protocol should include pulse
sequences which address the following issues:
assessment of focal and global cortical atrophy
as well as atrophy of the medial temporal lobe
(particularly the hippocampus); vascular white
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Table 1. Example of a multisequence MRI protocol for patients presenting to a memory clinic
3D-T1 with MPR Assessment of the medial temporal lobe on oblique coronal
reconstructions according to the axis of the hippocampus
Axial FLAIR (preferably 3D dataset) Assessment of vascular white matter changes, global and focal
cortical atrophy
Axial T2-(T)SE Assessment of vascular changes in deep gray matter structures
(e.g. lacunar infarctions of the thalamus)
Axial T2∗-GE Detection of microbleeds and macrohemorrhages
Axial DWI Detection of areas with restricted diffusion (e.g. acute stroke,
Creutzfeld–Jakob disease, Herpes encephalitis)
D = dimensional; DWI = diffusion-weighted imaging; FLAIR = fluid-attenuated inversion recovery; MPR =
multiplanar reconstructions; TSE = turbo spin echo; GE = gradient echo.
Table 2. Overview of the most established visual rating scales for the assessment of
cortical atrophy, hippocampal atrophy (medial temporal lobe atrophy, MTA) and white matter
hyperintensities (WMH)
CORTICAL ATROPHY MTA WMH
PASQUIER SCALE SCHELTENS SCALE FAZEKAS SCALE
.......................................................................................................................................................................................................................................................................................
Grade 0 Normal Normal No lesions
Grade 1 Widened sulci ↑ Width choroid fissure Punctiforme lesions
Grade 2 Widened sulci Volume ↑ Width of the choroid fissure Partially confluent lesions
loss of the gyri ↑ Width of the temporal horn
Grade 3 Knife blade atrophy ↑↑ Width of the choroid fissure Confluent lesions
↑↑ Width of the temporal horn
↑ Volume loss hippocampus
Grade 4 – ↑↑↑ Width of the choroid fissure –
↑↑ Width of the temporal horn
↑↑ Volume loss hippocampus
matter changes (small and large vessel disease);
vascular changes in deep gray matter structures
(in particular thalamus infarction); cerebral mi-
crobleeds (MBs) andmacrohemorrhages (including
post-traumatic changes). An example of a
possible MRI multisequence protocol is given in
Table 1.
How to read MRI scans in memory clinic patients
MRI scans in a clinical routine setting should
be read in a structured and reproducible way.
Regarding the two most relevant pathological
features in dementia (cortical atrophy including
medial temporal lobe atrophy and vascular
changes), visual rating scales have been established,
validated and are widely used in a clinical routine
setting. Table 2 summarizes the most established
rating scales for focal and global cortical atrophy,
hippocampal atrophy and vascular white matter
changes. In addition, certain aspects of MRI
pathology associated with cognition and normal
aging, such as the presence of MBs, should be
assessed and classified.
Cortical atrophy
Visual rating of cortical atrophy can be easily
performed using the four-point (0–3) Pasquier scale
(Pasquier et al., 1996) based on thewidth of the sulci
and volume of the gyri (Figure 1). The Pasquier
scale can be applied either globally (global cortical
atrophy) or regionally for certain anatomic regions
(temporal, parietal, etc.).
Medial temporal lobe atrophy
The visual rating of medial temporal lobe atrophy
is more sophisticated since we are dealing with
a complex interaction of rather small anatomic
structures and landmarks. The five-point Scheltens
scale, considering the width of the choroid fissure,
temporal horn as well as the volume of the
hippocampus, is a well-established rating scale for
the assessment of the medial temporal lobe, which
correlates well with histopathology and volumetric
measurements (Scheltens et al., 1992) (Figure 1).
Vascular pathology
The assessment of vascular changes is crucial in
the radiological evaluation of dementia patients,
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Figure 1.MRI ﬁndings in patients presenting with Alzheimer’s disease (AD). Top row: axial FLAIR (left) and oblique coronal reconstructions
(according to the axis of the hippocampus) of a 3D T1-weighted sequence (right) obtained from an 81-year-old male presenting with a
late-onset (senile) type of AD. On the FLAIR images, a severe global cortical atrophy (grade 2) can be observed. The cortical atrophy is more
prominent but not restricted to the parietal lobes. In addition, substantial (grade 2) atrophy of the hippocampus (widening of the choroid
ﬁssure in combination with a volume loss of the hippocampus) is present (arrows). Bottom row: comparable MR images obtained from
a 50-year-old male presenting with an early-onset (presenile) type of AD. In these patients a rather focal atrophy pattern involving the
parietal lobe (left, arrows), including the precuneus and the posterior cingulate, can be frequently observed, while the medial temporal
lobe structures are relatively spared (right, arrows).
particularly for the diagnosis of vascular dementia
(VaD) (van Straaten et al., 2004). However, small
vessel white matter changes which do not formally
fulfill the diagnostic criteria for VaD act in a
synergistic way with neurodegenerative changes
with relevant impact on clinical outcome measures
(Inzitari et al., 2009). FLAIR is the most sensitive
MRI sequence for the detection of white matter
hyperintensities (WMH) as a marker of small
vessel vascular damage. An easily applicable and
highly reproducible four-point rating scale (Fazekas
scale) is widely used in clinical practice and
corresponds well with more detailed ratings scales
and histopathology (Fazekas et al., 1987, Scheltens
et al., 1998). Another important marker of small
vessel disease, which has been included into the
NINDS-AIREN criteria for VaD, is the presence
of lacunar infarcts (Roma´n et al., 1993). These are
strongly associated with the presence and amount
of WMH and can be frequently found in the
cerebral deep whitematter, basal ganglia and crucial
anatomic structures such as the thalamus. Lacunes
in the white matter can also be sensitively detected
and differentiated from perivascular spaces on
FLAIR sequences (Figure 2). However, lacunes in
the infratentorial white matter and deep gray matter
structures (particularly the thalamus) are frequently
missed on FLAIR and therefore T2-weighted
(turbo) spin-echo sequences are mandatory for
these purposes (Bastos-Leite et al., 2004).
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Figure 2. Axial FLAIR images obtained from a 47-year-old female diagnosed with vascular dementia according to the NINDS-AIREN criteria.
On MRI, conﬂuent WMH (Fazakas grade 3) can be observed involving more than 25% of the white matter. Multiple lacunes (arrows) are
present in the deep white matter but also in the basal ganglia region. Note the severe involvement of the white matter of the anterior
temporal lobe suggestive of CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy). In
fact, a mutation in the Notch-3 gene was found in this patient.
Besides the assessment of small vessel disease, the
detection of large vessel disease, including territorial
infracts and watershed infarcts are of importance
since they have been incorporated into the NINDS-
AIREN criteria for VaD (Roma´n et al., 1993).
Cerebral microbleeds
MBs are defined as small hypointense dot-like
lesions in the brain parenchyma on T2∗-weighted or
susceptibility weighted MRI (SWI). Pathologically,
MBs represent perivascular hemosiderin deposits
stored in surrounding macrophages, presumably
due to pathological amyloid deposition in the
vascular wall leading to permeability and leakage.
Alternatively, MBs can also be seen in association
with small vessel disease, i.e. with hyperintense
vasculopathy. In terms of anatomic distribution
and the underlying pathophysiology, MBs can be
subdivided in lobar MBs located in the cortical
gray–white matter interface and non-lobar MBs
located in deep brain structures (e.g. basal ganglia)
and the posterior fossa (Figure 3). Lobar MBs
are related to cerebral amyloid angiopathy (CAA),
and almost invariably present in patients with
Alzheimer’s disease (AD), whereas non-lobar MBs
are more related to hypertensive vasculopathy
(Cordonnier and van der Flier, 2011). These two
different vasculopathies may co-occur in dementia
patients.
Depending on the sensitivity of the imaging tech-
nique (magnetic field strengths, pulse sequences,
echo time, spatial resolution), the prevalence of MB
in a normal elderly healthy population is almost
25% (Poels et al., 2011). In a memory clinic
population, the prevalence of MB is approximately
17%, ranging from 10% in patients with subjective
memory complaints, 18–20% in AD, to 65% in
patients with VaD (Cordonnier et al., 2006). In
general, MBs are associated with clinical outcome
measures, such as cognitive function and mortality,
age, apolipoprotein E genotype, cerebrospinal fluid
biomarkers, as well as vascular damage seen
on MRI, including WMH and lacunes (Goos
et al., 2009; 2010). In addition, there is emerging
evidence that lobar cortical MBs might have
predictive value in terms of the future development
of AD (Kirsch et al., 2009). It is also conceivable
that non-lobar MB might be a predictive factor of
VaD, but this remains to be investigated.
Amyloid-associated leakage from leptomeningeal
vessel leads to the pathological hemosiderin
deposition in the subpial space, which has
coined the term of superficial siderosis. On
T2∗-weighted and susceptibility-weighted MRI,
superficial siderosis can be identified by low signal
abnormalities in the subpial space lining the surface
of the brain. Similar to lobar hemorrhage and MBs,
superficial siderosis seems to be a marker for CAA
(Linn et al., 2010) (Figure 3). Its prevalence is rather
lower than 1% among a normal healthy population
and there is strong co-incidence with lobar MBs
(Vernooij et al., 2009). However, compared to
MBs, the clinical and prognostic role of superficial
siderosis in dementia patients is rather unclear and
needs further investigation.
Use of MRI to support the diagnosis of
neurological disease associated with dementia
Beside the assessment of normal aging findings
(mild global cortical and hippocampal atrophy and
WMH), MRI is helpful to support the clinical
diagnosis of neurodegenerative, inflammatory and
metabolic disease associated with dementia, by
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Figure 3. Axial SWI images presenting different types of microbleeds (MBs). (A) MBs (arrows) located in the deep white and gray
matter structures (non-lobar) are associated with hypertensive encephalopathy whereas (B) MBs (arrows) located in the white matter–
cortcial gray matter interface are rather associated with cerebral amyloid angiopathy (CAA). (C) Superﬁcial siderosis (open head arrows)
represents a leptomeningeal manifestation of CAA. In this patient, lobar MBs (closed head arrows) are located close to the areas of
superﬁcial siderosis.
showing specific atrophy patterns and white and/or
gray matter changes. Here we describe the MRI
pathology of the most frequent diseases associated
with dementia.
Alzheimer’s disease
AD is the most common cause of dementia
and is characterized by the histopathological
hallmarks of amyloid-β and hyperphophorylated
tau accumulation (McKhann et al., 1984). The
role of neuroimaging in the diagnosis of AD is
becoming increasingly important. This is reflected
in new proposed diagnostic criteria in which, as
well as cerebrospinal fluid (CSF) (amyloid-β42, tau
or phospho-tau) and positron emission tomography
(PET) findings (temporo-parietal hypometabolism
on FDG-PET, amyloid imaging), a structural
imaging marker (medial temporal lobe atrophy) has
been included as a key criterion for the diagnosis of
AD (Dubois et al., 2007).
Corresponding to the neuropathological stages
described by Braak and Braak (1991), the
neurodegenerative changes in terms of atrophy in
senile ADpatients can be detected first in themedial
temporal lobe, particularly in the hippocampus and
best seen on oblique coronal T1-weighted images.
Although MTA is very characteristic for AD, a
normal volume of the medial temporal lobe does
not exclude AD. In addition, MTA is a common
feature in other neurodegenerative disorders and
is therefore not a specific marker to confidently
exclude other neurodegenerative disease associated
with dementia. Besides the diagnostic hallmark
MTA, cortical atrophy predominantly located in
the parietal lobes is a common radiological feature
and may be helpful in differentiating AD from
other neurodegenerative diseases associated with
dementia (Jones et al., 2006; Frisoni et al., 2007)
(Figure 1). The degree of cortical atrophy andMTA
can be easily assessed by visual rating, as described
above, and corresponds well with histopathology.
Visual rating of MTA in a memory clinic population
in order to distinguish AD patients from those
without cognitive complaints provides sensitivity
and specificity values of 80–85% (Frisoni et al.,
2010).
Compared to classical senile AD manifestations,
early-onset (pre-senile) AD may present with a
different distinct atrophy pattern predominantly
involving the parietal cortex, precuneus and
posterior cingulum and relatively sparing the medial
temporal lobe (Figure 1). In advanced stages, the
medial temporal lobe becomes more and more
affected (Karas et al.; 2007; Shiino et al., 2008).
In patients with mild cognitive impairment
(MCI) who present with cognitive impairment
not fulfilling the diagnostic criteria for dementia,
the degree of cortical and hippocampal atrophy
measured by visual rating has a strong predictive
value for further cognitive decline and development
of AD (Likeman et al., 2005; Bouwman et al., 2007;
Davatzikos et al.; 2010).
It is important to realize that the vast majority
of patients with AD pathology present with a
combination of neurodegenerative changes and
vascular pathology, such as WMH and lacunar
infarcts. This vascular co-morbidity has prompted
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the pathophysiological concept that AD patients
do not usually present with a “pure Alzheimer
pathology,” which has coined the term of “mixed
pathology” (de la Torre, 2004; DeCarli, 2006). This
concept is further supported by the distribution
of MBs in AD patients. The vast majority
of MBs is located in lobar regions in the
cortical white–gray matter interface, suggesting
CAA pathology which is strongly associated with
AD. However, a substantial proportion of MBs is
located in non-lobar regions, suggesting underlying
microangiopathy due to vasculo-ischemic damage.
In fact, these findings further support the concept of
“mixed pathology” and the clinical impression that
amyloid pathology and cerebrovascular pathology
are likely acting in a synergistic way (Kalaria and
Ballard, 1999).
Fronto-temporal lobe degeneration
The disease entity of fronto-temporal lobe degener-
ation (FTLD) consists of three different and distinct
clinical subtypes: the behavioral variant of fronto-
temporal dementia (bvFTD), progressive aphasia
(PA) and semantic dementia (SD). These subtypes
present with different clinical manifestations and
also different atrophy patterns on MRI (Neary
et al., 1998). The bvFTD is radiologically
characterized by (bilateral) atrophy of the frontal
lobes, including the dorsolateral, frontobasal and
mesofrontal cortical areas, as well as of the
anterior parts of the temporal lobes (Figure 4).
PA is a non-fluent aphasia characterized by left-
sided (most often) atrophy of the lateral parts of
the temporal lobe, basal parts of the frontal lobe
and the insular cortex, resulting in a unilateral
widening of the Silvian fissure (Gorno-Tempini
et al., 2011). Semantic aphasia is a progressive form
of fluent-aphasia and shows focal cortical atrophy of
the anterior parts of the temporal lobes (temporal
pole), more frequently on the left side than on
the right side (Figure 4). These atrophy patterns
correlate well with quantitative MRI methods, such
as voxel-based morphometry (VBM), and with
pathological studies.
In early disease stages, structural neuroimaging
can be normal and/or shows unspecific global
cortical atrophy, as seen in other dementias.
In these stages, PET imaging may already
reveal relevant glucose hypometabolism in fronto-
temporal regions. The focal cortical atrophy pattern
may develop slightly over time and become more
evident in later disease stages. Also, medial temporal
lobe structures such as the hippocampus and the
amygdala are frequently affected. In patients with
end-stage atrophy, a “ballooning” of the temporal
horn can be observed, which is surrounded by a
small confluent area of high signal in the white
matter on T2-weighted images (Rosen et al., 2002;
Vitali et al., 2008) (Figure 4).
Dementia associated with parkinsonian
dementias
Most of the parkinsonian syndromes are associated
with cognitive decline and dementia, including
idiopathic Parkinson’s disease, dementia with
Lewy bodies (DLB), multisystem atrophy (MSA),
corticobasal degeneration (CBD) and progressive
supranuclear palsy (PSP).
DEMENTIA WITH LEWY BODIES
DLB is a frequent neurodegenerative disease
associated with dementia, which is pathologically
characterized by α-synuclein-positive Lewy body
inclusions in the cortical gray matter. Clinically,
DLB patients present with progressive cognitive
impairment mainly affecting memory as well
as visuo-spatial and executive domains, with
fluctuations of symptoms combined with visual
hallucinations and often sleeping disorders.
Structural neuroimaging has limited value in the
diagnosis of DLB. Most patients show mild to
moderate global cortical atrophy, while the medial
temporal lobe is relatively preserved (Figure 5).
However, considering this atrophy pattern, there is
substantial overlap between DLB and AD as well
as normal aging. This overlap can be overcome by
more specific imaging techniques, such asmolecular
imaging of the dopaminergic system (e.g. dopamine
transporter imaging,DAT), allowing amore specific
diagnosis of DLB.
MULTISYSTEM ATROPHY
Clinical characteristics of MSA include orthostatic
hypotension, urine incontinence, and cerebellar
symptoms. Imaging criteria of MSA consist of focal
atrophy of the basal ganglia, in particular of the
putamen, as well as the cerebellar peduncles (most
obvious in the middle cerebellar peduncle), brain
stem and cerebellum. On T2-weighted images of
some MSA patients, linear signal abnormalities can
be observed in white matter lateral to the putamen
(“putaminal rim sign”), pons (“hot cross bun sign”)
and cerebellar peduncles, which can further support
the clinical diagnosis of MSA (Figure 6) (Vitali
et al., 2008).
CORTICAL DEGENERATION
Patients with CBD typically present with asym-
metric cortical symptoms, including language and
speech disturbances, visuo-spatial deficits and
hemineglect, apraxia and occasionally myclonus,
together with extra pyramidal signs. On MRI, CBD
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Figure 4. Axial FLAIR (left column) and oblique coronal reconstruction of a 3D T1-weighted sequence (right column) presenting different
types of fronto-temporal lobe degeneration (FTLD). Top row: a 56-year-old female presenting with bvFTD. Note the focal atrophy of the
frontal lobes (particularly of the mesofrontal area) (arrows). Atrophy of the medial temporal lobe structures (open head arrows) can also
be observed in these patients and deﬁnitely does not exclude FTLD. Bottom row: a 76-year-old female presenting with semantic dementia.
OnMRI, a severe focal and asymmetric atrophy of the left temporal lobe can be observed in the vast majority of cases (open head arrows).
In particular the temporal pole is affected. Ballooning of the temporal horn and a small rim of high signal on the FLAIR/T2-weighted images
can be seen around the temporal horn, which is probably a gliotic reaction as a consequence of end-stage atrophy (arrows).
Figure 5. Axial FLAIR (left) and oblique coronal reconstruction of a 3D T1-weighted sequence (right) obtained from a 75-year-old male
with DLB. Note the mild to moderate global cortical atrophy and the relative sparing of the hippocampus.
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Figure 6. Axial T2-weighted (left) and sagittal T1-weightedMR images (middle and right) in a patient presentingwithmultisystem atrophy.
Note the severe atrophy of the brain stem and the cerebellum, including the middle cerebellar peduncle (arrows). In the pons, two linear
areas with high signal (“hot cross bun sign”) can be detected on the T2-weighted image.
Figure 7. Axial T2-weighted and sagittal T1-weighted MR images of a patients with the diagnosis of progressive supranuclear palsy
demonstrating mesencephalic atrophy (reduced gap diameter, increased interpeduncular angle), while the pons is relatively preserved.
This atrophy pattern resembles the head and body of a humming bird, which has coined the term “humming bird” sign (arrow).
patients frequently show an asymmetric cortical
atrophy of the parietal and frontal cortex,while
the temporal lobe, including the medial temporal
lobe, is relatively spared. The left side seems to be
involved more frequently, and VBM analysis has
shown that the neurodegenerative changes are most
pronounced at the interface between the superior
frontal and precentral sulci (Boxer et al., 2006)
PROGRESSIVE SUPRANUCLEAR PALSY
PSP is clinically characterized by vertical eye
movement disturbances and postural instability.
MRI frequently shows indirect and direct evidence
of mid-brain atrophy (Figure 7). An often used
and reproducible MRI parameter is the anterior–
posterior diameter of the mid-brain, which is
significantly reduced in PSP patients. Different
cut-off values of the anterior–posterior midbrain
diameter have been reported. A diameter shorter
than 15 mm measured in the mid-sagittal view
has been well established and validated in a PSP
population. In addition, a reduced volume of
the cerebral peduncles and an increased inter-
peduncular angle can be observed (Warmuth-Metz
et al., 2001; Oba et al., 2005). However, mid-
brain atrophy is a rather non-specific feature in
the diagnosis of PSP since other neurodegenerative
diseases, including CBD and MSA, can present
with mid-brain atrophy, resulting in a considerable
overlap. Studies also considering other key
structures such as the middle and superior
cerebellar peduncles were able to better differentiate
PSP from MSA and Parkinson’s disease.
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Vascular dementia
Vascular dementia (VaD) is probably the most
common cause of dementia after AD. Clinically,
VaD is characterized by memory impairment and
dysfunction of other cognitive domains, particularly
frontal-executive functions. Neuroimaging plays a
key role in the diagnosis of VaD. CT and, more
sensitively, MRI are able to make the diagnosis
of VaD according to diagnostic criteria and can
distinguish pure VaD pathology from vascular
comorbidity in terms of “mixed pathology.” Within
the group of VaD patients, the distinct pattern
of distribution of vascular lesions can lead to
a specific diagnosis of the underlying disease
causing VaD, e.g. CADASIL (cerebral autosomal
dominant arteriopathy with subcortical infarcts
and leukoencephalopathy) (Chabriat et al., 1998)
(Figure 2).
Diagnostic criteria for VaD have been proposed
with differing sensitivity and sensibility (Pohjasvaara
et al., 2000). The NINDS-AIREN criteria have
been developed for establishing the diagnosis
of VaD in research studies and clearly state
that neuroimaging is an essential part of the
diagnostic process of VaD. According to these
criteria, patients can be classified as possible,
probable and definite VaD. The NINDS-AIREN
criteria are based on three main features: the
presence of dementia, evidence of cerebro-vascular
disease either clinically or in MRI/CT, and the
temporal relationship between the clinical onset
of dementia and the cerebrovascular disease.
Radiologically, VaD can be diagnosed based on the
presence of small vessel disease (WMH affecting
at least 25% of the white matter, multiple basal
ganglia and frontal white matter lacunes, bilateral
thalamic lesions) and large vessel disease (territorial
and watershed infarcts) (Guermazi et al., 2007).
Regarding the latter, both the severity (e.g. bilateral)
and location (e.g. dominant hemisphere and
involving association cortex) are crucial parameters.
However, the diagnosis within strict diagnostic
criteria remains a matter for debate. The temporal
relationship between vascular damage (e.g. stroke)
and cognitive decline is difficult to determine in
many cases since a substantial number of strokes
and, moreover, progression of WMH is silent.
In addition, chronic hemodynamic conditions
leading to cerebral hypoperfusion (e.g. carotid
stenosis) may cause cognitive impairment and
dementia without any vascular changes stated in the
diagnostic criteria (Johnston et al., 2004). Elderly
patients with dementia who fulfill the clinico-
radiological diagnostic criteria of VaD in particular
also show changes consistent with AD pathology,
which again reinforces the concept of “mixed
dementia.” Another possible limitation of VaD
diagnostic criteria is that MBs, which are associated
with cognitive deficits in several populations, are
currently not being considered.
Despite the difficulties and problems in the
diagnosis of VaD, neuroimaging has become crucial
in identifying certain patterns of vascular damage
causing VaD, as well as identifying underlying
vascular pathology in the early disease course, which
might have therapeutic consequences (Tzourio
et al., 2003).
Dementia secondary to inflammation
Besides primary neurodegenerative diseases associ-
ated with dementia, cognitive decline is commonly
associated with neuroinflammatory and infectious
disease of the central nervous system, including
multiple sclerosis, herpes simplex infections,
progressive multifocal leukoencephalopathy (PML)
and prion diseases. Concerning the diagnosis of
prion diseases such as Creutzfeld-Jakob disease
(CJD), MRI has become one of the most important
diagnostic methods. Depending on the clinical
subtype of CJD, different patterns of high signal
abnormalities on FLAIR and T2-weighted imaging
can be observed in the cortical gray matter and
the basal ganglia, particularly the striatum and
thalamus (Figure 8). The abnormalities show
features of restricted extracellular diffusion with
a high signal on diffusion-weighted imaging and
corresponding low apparent diffusion coefficient
(ADC) values (Shiga et al., 2004). Different
patterns of gray matter involvement on MRI
in sporadic (sCJD), genetic and variant (vCJD)
forms of CJD have been described (Zeidler et al.,
2000; Tschampa et al., 2007). Based on pattern
recognition, MRI diagnosis of CJD can be made
with a high sensitivity and specificity beyond
90%. Therefore, MRI may not only support the
clinical diagnosis of CJD, but also allow a rather
specific diagnosis of CJD in combination with other
biomarkers, including the CSF (14–3-3 protein)
and electroencephalogram.
Serial MRI
The atrophy patterns in neurodegenerative disease
described above are based on cross-sectional MRI.
In neurodegenerative diseases such as AD, the
atrophy rate is more accelerated when compared
to normal aging brains. Therefore, serial MRI
examinations can assess atrophy progression during
follow-up, which can further support the clinical
diagnosis, particularly in early disease stages when
the neurodegenerative findings might be rather
discrete (Jack et al., 1998; Riidha et al., 2006).
With the advent of more specific imaging methods
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Figure 8. A 54-year-old female presenting with a cortical variant of Creutzfeldt-Jakob disease. The axial FLAIR (left) and more sensitively
the DWI sequence (right) shows high signal abnormalities in the cortical gray matter of both hemispheres, more pronounced in the left
parietal lobe (arrows).
such as FDG-PET and amyloid-PET for these
purposes, the need for serial MRI in order to
support the diagnosis is substantially decreasing.
However, atrophy progression assessed by MRI is
increasingly used as a safety and efficacy outcome
measure in clinical trials (Frisoni et al., 2010).
Conclusion
Structural MRI has become a crucial part of the
diagnostic evaluation of memory clinic patients,
which is reflected by current guidelines dealing with
the diagnosis of dementia. Similar to CT, MRI
can exclude possibly (surgically) treatable causes of
dementia and also show distinct atrophy patterns
and cerebrovascular changes that can support the
clinical diagnosis of dementia. For these purposes,
visual rating scales have been established and
allow a fast, reliable and reproducible assessment.
However, MRI has substantial advantages over CT
and can demonstrate certain aspects of pathology
associated with dementia, such as MBs as a marker
of CAA associated with AD pathology and/or
vascular damage. In addition, MRI is able to
further characterize the amount and distribution
of cerebrovascular pathology, which impacts the
diagnosis, prognosis and therapeutic strategy in
these patients. In some disease entities, such as
prion disease, MRI has become the key diagnostic
modality for a sensitive and specific diagnosis.
Despite the high value of structural MRI in
the diagnostic scheme of memory clinic patients,
advanced and quantitative imaging modalities,
including PET and quantitative MRI techniques
discussed elsewhere in this special issue, will shed
further light on the dynamic field of the possibilities
and challenges of neuroimaging in dementia.
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